Table 3.
Self-reported medications and medications recorded in the medical record for Indigenous and non-Indigenous participants
| Pharmacotherapy details | Indigenous (n=59) | Non-Indigenous (n=27) |
| Self-reported puffer/Inhaler | 57 (97%) | 23 (85%) |
| Self-reported puffer/Inhaler could identify | 48 (81%) | 23 (85%) |
| Medical record of any medication | 57 | 27 |
| Medical record of SABA | 56 (98%) | 27 (100%) |
| Medical record of SAMA | 12 (21%) | 7 (26%) |
| Medical record of LABA | 43 (75%) | 21 (78%) |
| Medical record of LAMA | 29 (51%) | 18 (67%) |
| Medical record of ICS | 37 (65%) | 19 (70%) |
| Self-reported tablets | 4 (7%) | 3 (11%) |
| Medical record of theophylline | 1 (2%) | 1 (4%) |
| Self-reported home oxygen (DOT) | 1 (2%) | 5 (19%) |
| Medical record of home oxygen (DOT) | 5 (9%) | 9 (33%) |
| Self-reported multiple medications | 35 (61%) | 14 (52%) |
| Medical record of multiple medications | 49 (86%) | 25 (93%) |
| Symptomatic use self-reported | 50 (88%) | 23 (85%) |
| Daily use recommended (LABA/LAMA) | 44 | 23 |
| Daily use self-reported | 9 (20%) | 6 (26%) |
DOT, domiciliary oxygen therapy; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; SABA, short-acting bronchodilator; SAMA, short-acting muscarinic antagonists.